Format

Send to

Choose Destination
Drug Discov Today. 2015 Dec;20(12):1422-8. doi: 10.1016/j.drudis.2015.08.005. Epub 2015 Aug 28.

Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.

Author information

1
Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, USA; Weill Cornell Medical College, NY, USA.
2
Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, USA; Weill Cornell Medical College, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY, USA; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, USA.
3
Department of Pathology, Memorial Sloan Kettering Cancer Center, NY, USA.
4
Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, USA; Weill Cornell Medical College, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY, USA.
5
Weill Cornell Medical College, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY, USA; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, USA.
6
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, NY, USA. Electronic address: ladanyim@mskcc.org.

Abstract

Implementing a center-wide precision medicine strategy at a major cancer center is a true multidisciplinary effort and requires comprehensive alignment of a broad screening strategy with a clinical research enterprise that can use these data to accelerate development of new treatments. Here, we describe the genomic screening approach at Memorial Sloan Kettering Cancer Center, a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology designated MSK-IMPACT, and how it enables and supports a large clinical trial portfolio enriched for multi-histology, biomarker-selected, 'basket' studies of targeted therapies.

PMID:
26320725
PMCID:
PMC4940024
DOI:
10.1016/j.drudis.2015.08.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center